This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boulay, A. Articles by Lane, H. A. Search for Related Content PubMed PubMed Citation Articles by Boulay, A. Articles by Lane, H. A.

Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells

¹Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland, and ²Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland

The orally bioavailable rapamycin derivative RAD001 (everolimus) targets the mammalian target of rapamycin pathway and possesses potent immunosuppressive and anticancer activities. Here, the antitumor activity of RAD001 was evaluated in the CA20948 syngeneic rat pancreatic tumor model. RAD001 demonstrated dose-dependent antitumor activity with daily and weekly administration schedules; statistically significant antitumor effects were observed with 2.5 and 0.5 mg/kg RAD001 administered daily [treated tumor versus control tumor size (T/C), 23% and 23–30%, respectively], with 3–5 mg/kg RAD001 administered once weekly (T/C, 14–36%), or with 5 mg/kg RAD001 administered twice weekly (T/C, 36%). These schedules were well tolerated and exhibited antitumor potency similar to that of the cytotoxic agent 5-fluorouracil (T/C, 23%). Moreover, the efficacy of intermittent treatment schedules suggests a therapeutic window allowing differentiation of antitumor activity from the immunosuppressive properties of this agent. Detailed biochemical profiling of mammalian target of rapamycin signaling in tumors, skin, and peripheral blood mononuclear cells (PBMCs), after a single administration of 5 mg/kg RAD001, indicated that RAD001 treatment blocked phosphorylation of the translational repressor eukaryotic initiation factor 4E-binding protein 1 and inactivated the translational activator ribosomal protein S6 kinase 1 (S6K1). The efficacy of intermittent treatment schedules was associated with prolonged inactivation of S6K1 in tumors and surrogate tissues (72 h). Furthermore, detailed analysis of the dose dependency of weekly treatment schedules demonstrated a correlation between antitumor efficacy and prolonged effects (7 days) on PBMC-derived S6K1 activity. Analysis of human PBMCs revealed that S6K1 also underwent a concentration-dependent inactivation after RAD001 treatment ex vivo (>95% inactivation with 20 nM RAD001). In contrast, human PBMC-derived eukaryotic initiation factor 4E-binding protein 1 was present predominantly in the hypophosphorylated form and was unaffected by RAD001 treatment. Taken together, these results demonstrate a correlation between the antitumor efficacy of intermittent RAD001 treatment schedules and prolonged S6K1 inactivation in PBMCs and suggest that long-term monitoring of PBMC-derived S6K1 activity levels could be used for assessing RAD001 treatment schedules in cancer patients.

This article has been cited by other articles:

				C. R. Schnell, F. Stauffer, P. R. Allegrini, T. O'Reilly, P. M.J. McSheehy, C. Dartois, M. Stumm, R. Cozens, A. Littlewood-Evans, C. Garcia-Echeverria, et al. Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging Cancer Res., August 15, 2008; 68(16): 6598 - 6607. [Abstract] [Full Text] [PDF]

				A. Vazquez-Martin, C. Oliveras-Ferraros, R. Colomer, J. Brunet, and J. A. Menendez Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells Ann. Onc., June 1, 2008; 19(6): 1097 - 1109. [Abstract] [Full Text] [PDF]

				A. O'Donnell, S. Faivre, H. A. Burris III, D. Rea, V. Papadimitrakopoulou, N. Shand, H. A. Lane, K. Hazell, U. Zoellner, J. M. Kovarik, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors J. Clin. Oncol., April 1, 2008; 26(10): 1588 - 1595. [Abstract] [Full Text] [PDF]

				J. Tabernero, F. Rojo, E. Calvo, H. Burris, I. Judson, K. Hazell, E. Martinelli, S. R. y Cajal, S. Jones, L. Vidal, et al. Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors J. Clin. Oncol., April 1, 2008; 26(10): 1603 - 1610. [Abstract] [Full Text] [PDF]

				S. Sleijfer and E. Wiemer Dose Selection in Phase I Studies: Why We Should Always Go for the Top J. Clin. Oncol., April 1, 2008; 26(10): 1576 - 1578. [Full Text] [PDF]

				C. Gridelli, P. Maione, and A. Rossi The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer Oncologist, February 1, 2008; 13(2): 139 - 147. [Abstract] [Full Text] [PDF]

				A. Schayowitz, G. Sabnis, V. C.O. Njar, and A. M.H. Brodie Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro Mol. Cancer Ther., January 1, 2008; 7(1): 121 - 132. [Abstract] [Full Text] [PDF]

				M. Fouladi, F. Laningham, J. Wu, M. A. O'Shaughnessy, K. Molina, A. Broniscer, S. L. Spunt, I. Luckett, C. F. Stewart, P. J. Houghton, et al. Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors J. Clin. Oncol., October 20, 2007; 25(30): 4806 - 4812. [Abstract] [Full Text] [PDF]

				B. E. Johnson, D. Jackman, and P. A. Janne Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non Small Cell Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4628s - 4631s. [Abstract] [Full Text] [PDF]

				S. Mabuchi, D. A. Altomare, M. Cheung, L. Zhang, P. I. Poulikakos, H. H. Hensley, R. J. Schilder, R. F. Ozols, and J. R. Testa RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model Clin. Cancer Res., July 15, 2007; 13(14): 4261 - 4270. [Abstract] [Full Text] [PDF]

				J. M. Campistol, J. Albanell, W. Arns, I. Boletis, J. Dantal, J. W. de Fijter, S. A. Mortensen, H.-H. Neumayer, O. Oyen, J. Pascual, et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i36 - i41. [Abstract] [Full Text] [PDF]

				A. Gutierrez-Dalmau and J. M. Campistol The role of proliferation signal inhibitors in post-transplant malignancies Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i11 - i16. [Abstract] [Full Text] [PDF]

				C. Xie, R. Patel, T. Wu, J. Zhu, T. Henry, M. Bhaskarabhatla, R. Samudrala, K. Tus, Y. Gong, H. Zhou, et al. PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr Int. Immunol., April 1, 2007; 19(4): 509 - 522. [Abstract] [Full Text] [PDF]

				F. Rojo, L. Najera, J. Lirola, J. Jimenez, M. Guzman, M. D. Sabadell, J. Baselga, and S. R. y Cajal 4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis Clin. Cancer Res., January 1, 2007; 13(1): 81 - 89. [Abstract] [Full Text] [PDF]

				C. Cao, T. Subhawong, J. M. Albert, K. W. Kim, L. Geng, K. R. Sekhar, Y. J. Gi, and B. Lu Inhibition of Mammalian Target of Rapamycin or Apoptotic Pathway Induces Autophagy and Radiosensitizes PTEN Null Prostate Cancer Cells. Cancer Res., October 15, 2006; 66(20): 10040 - 10047. [Abstract] [Full Text] [PDF]

				M. Hidalgo, J. C. Buckner, C. Erlichman, M. S. Pollack, J. P. Boni, G. Dukart, B. Marshall, L. Speicher, L. Moore, and E. K. Rowinsky A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer. Clin. Cancer Res., October 1, 2006; 12(19): 5755 - 5763. [Abstract] [Full Text] [PDF]

				K. W.L. Yee, Z. Zeng, M. Konopleva, S. Verstovsek, F. Ravandi, A. Ferrajoli, D. Thomas, W. Wierda, E. Apostolidou, M. Albitar, et al. Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies Clin. Cancer Res., September 1, 2006; 12(17): 5165 - 5173. [Abstract] [Full Text] [PDF]

				D. Valmori, V. Tosello, N. E. Souleimanian, E. Godefroy, L. Scotto, Y. Wang, and M. Ayyoub Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells J. Immunol., July 15, 2006; 177(2): 944 - 949. [Abstract] [Full Text] [PDF]

				J. A. Sosman and I. Puzanov Molecular targets in melanoma from angiogenesis to apoptosis. Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s. [Abstract] [Full Text] [PDF]

				K. E. O'Reilly, F. Rojo, Q.-B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, et al. mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt Cancer Res., February 1, 2006; 66(3): 1500 - 1508. [Abstract] [Full Text] [PDF]

				C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689. [Abstract] [Full Text] [PDF]

				S. Chan, M. E. Scheulen, S. Johnston, K. Mross, F. Cardoso, C. Dittrich, W. Eiermann, D. Hess, R. Morant, V. Semiglazov, et al. Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer J. Clin. Oncol., August 10, 2005; 23(23): 5314 - 5322. [Abstract] [Full Text] [PDF]

				A. A. Adjei and M. Hidalgo Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy J. Clin. Oncol., August 10, 2005; 23(23): 5386 - 5403. [Abstract] [Full Text] [PDF]

				K. Homicsko, A. Lukashev, and R. D. Iggo RAD001 (Everolimus) Improves the Efficacy of Replicating Adenoviruses that Target Colon Cancer Cancer Res., August 1, 2005; 65(15): 6882 - 6890. [Abstract] [Full Text] [PDF]

				A. Boulay, J. Rudloff, J. Ye, S. Zumstein-Mecker, T. O'Reilly, D. B. Evans, S. Chen, and H. A. Lane Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer Clin. Cancer Res., July 15, 2005; 11(14): 5319 - 5328. [Abstract] [Full Text] [PDF]

				S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann. Onc., April 1, 2005; 16(4): 525 - 537. [Abstract] [Full Text] [PDF]

				R. K. Goudar, Q. Shi, M. D. Hjelmeland, S. T. Keir, R. E. McLendon, C. J. Wikstrand, E. D. Reese, C. A. Conrad, P. Traxler, H. A. Lane, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Mol. Cancer Ther., January 1, 2005; 4(1): 101 - 112. [Abstract] [Full Text] [PDF]

				N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, D. Chauhan, C. Mitsiades, K. Podar, S. Le Gouill, P. Richardson, N. C. Munshi, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma Blood, December 15, 2004; 104(13): 4188 - 4193. [Abstract] [Full Text] [PDF]

				M. Hidalgo New Target, New Drug, Old Paradigm J. Clin. Oncol., June 15, 2004; 22(12): 2270 - 2272. [Full Text] [PDF]